07:00 , Jun 6, 2011 |  BC Week In Review  |  Clinical News

p28: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 15 evaluable patients showed that thrice-weekly IV p28 for 4 weeks produced 1 complete response and 7 partial responses. No serious adverse events were reported. Patients received...